NEW YORK (GenomeWeb) – Trovagene announced today that it has completed a reorganization effort that it believes will allow it to refocus its efforts on the global distribution of liquid biopsy kits and systems to clinical research laboratories.

The company — which also cut 20 jobs — estimated that the staff reductions, combined with a lowering of expenses associated with marketing CLIA lab testing directly to medical professionals, will reduce its annual pre-tax expenses by approximately $4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.